News

Company Commences Phase 2 Study at Multiple Academic Sites in United States Haddonfield NJ, October 13, 2020--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company [...]

Linnaeus announced today announced that it has entered into a clinical collaboration agreement with Merck to evaluate the combination of its lead investigational product candidate LNS8801, and Merck’s anti-PD-1 therapy, KEYTRUDA®(pembrolizumab) in patients with [...]

Linnaeus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma who have progressed on or [...]

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Pancreatic Cancer Data in Cellular and Molecular Gastroenterology and Hepatology Haddonfield NJ, June 10, 2020 -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately [...]

Linnaeus Therapeutics Announces First Patient Dosed in Its Phase 1/2 Clinical Trial of LNS8801 in Patients with Advanced Cancer Company Commences First-in-Human Study at Multiple Academic [...]

Linnaeus Therapeutics Announces FDA Clearance of Investigational New Drug Application for LNS8801 Haddonfield NJ, September 24, 2019--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held, clinical-stage biopharmaceutical company [...]